Furthermore, a recent population-based cohort study in Denmark on more than 56,000 inflammatory bowel disease patients reported that there is no significant risk of cancer when treated with TNF-α antagonists such as infliximab, adalimumab, and certolizumab pegol [41]. Here, TNF is linked to cancer.